These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27044813)

  • 21. Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells.
    Azouz A; Wu YL; Hillion J; Tarkanyi I; Karniguian A; Aradi J; Lanotte M; Chen GQ; Chehna M; Ségal-Bendirdjian E
    Leukemia; 2010 Mar; 24(3):613-22. PubMed ID: 20072159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.
    Westervelt P; Pollock JL; Oldfather KM; Walter MJ; Ma MK; Williams A; DiPersio JF; Ley TJ
    Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9468-73. PubMed ID: 12077315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
    Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
    Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
    Niitsu N; Ishii Y; Matsuda A; Honma Y
    Cancer Res; 2001 Jan; 61(1):178-85. PubMed ID: 11196157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays.
    Nouzova M; Holtan N; Oshiro MM; Isett RB; Munoz-Rodriguez JL; List AF; Narro ML; Miller SJ; Merchant NC; Futscher BW
    J Pharmacol Exp Ther; 2004 Dec; 311(3):968-81. PubMed ID: 15302897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute promyelocytic leukemia: from clinic to molecular biology.
    Chen SJ; Wang ZY; Chen Z
    Stem Cells; 1995 Jan; 13(1):22-31. PubMed ID: 7719245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells.
    Wang L; Xiao H; Zhang X; Liao W; Fu S; Huang H
    Int J Oncol; 2015 Nov; 47(5):1685-95. PubMed ID: 26397153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
    Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
    Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the histone deacetylase complex in acute promyelocytic leukaemia.
    Lin RJ; Nagy L; Inoue S; Shao W; Miller WH; Evans RM
    Nature; 1998 Feb; 391(6669):811-4. PubMed ID: 9486654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells.
    Awwad RT; Do K; Stevenson H; Fu SW; Lo-Coco F; Costello M; Campbell CL; Berg PE
    Ann Hematol; 2008 Mar; 87(3):195-203. PubMed ID: 18026954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling.
    Savickiene J; Treigyte G; Jazdauskaite A; Borutinskaite VV; Navakauskiene R
    Cell Biol Int; 2012 Nov; 36(11):1067-78. PubMed ID: 22845560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
    Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
    Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
    Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.
    Rego EM; Ruggero D; Tribioli C; Cattoretti G; Kogan S; Redner RL; Pandolfi PP
    Oncogene; 2006 Mar; 25(13):1974-9. PubMed ID: 16331271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ATRA(ouble) in the treatment of acute promyelocytic leukemia.
    Ozpolat B; Lopez-Berestein G; Mehta K
    J Biol Regul Homeost Agents; 2001; 15(2):107-22. PubMed ID: 11501968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens.
    Hecht A; Doll S; Altmann H; Nowak D; Lengfelder E; Röllig C; Ehninger G; Spiekermann K; Hiddemann W; Weiß C; Hofmann WK; Nolte F; Platzbecker U
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):889-896.e5. PubMed ID: 28923666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression.
    Xu K; Guidez F; Glasow A; Chung D; Petrie K; Stegmaier K; Wang KK; Zhang J; Jing Y; Zelent A; Waxman S
    Cancer Res; 2005 Sep; 65(17):7856-65. PubMed ID: 16140955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
    Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
    Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.